Anderlecht

• A Phase 3 Study of NTLA 2001 in participants with amyloidosis with cardiac muscle disease. Halted
  2023-507220-23-00 5 2024-07-26 Transthyretin Amyloidosis with Cardiomyopathy
• A Phase 1 Study of ATV-1601, in Patients with Advanced Cancer that have AKT1 E17K Mutations Ended
  2025-521480-12-00 1 2025-10-22 Advanced solid tumors, Breast Cancer
• A First-in-human study to learn how safe the study drug BAY2965501 is, find the best dose (single drug & combination), how it affects the bo … Ended
  2023-507905-33-00 1 2025-09-30 Advanced solid tumors
• A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients with Overt Hepatic Encep … Ended
  2025-521029-34-00 4 2025-09-18 Patients with overt hepatic encephalopathy (OHE) and acute decompensat
• A phase III, international, multiCenter, randomized, paraLlel-group, Endoscopist-blinded non-inferiority study of the efficAcy, safety and p … Ended
  2025-521451-23-00 5 2025-09-03 Subjects scheduled for elective colonoscopy performed according to ESG
• Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents with Sickle Cell Disease during Vaso-Occlusive Crisis Ended
  2024-513440-29-00 10 2025-06-25 Sickle cell disease vaso-occlusive crisis
• A randomised, double-blind, placebo controlled, parallel group, multi-centre trial in adult subjects with newly diagnosed type 1 diabetes me … Ended
  2023-506545-27-01 4 2025-01-28 Diabetes mellitus, Type 1
• BATOLISA Ended
  2024-513529-21-00 6 2025-01-24 Lipedema
• A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as … Ended
  2024-511557-21-00 5 2024-11-14 Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole Compared to Letrozole Alone in Postmenopausal Wom … Ended
  2024-512848-30-00 4 2024-11-12 HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER
• A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Modera … Ended
  2023-505433-27-00 5 2024-08-13 Atopic Dermatitis
• A Phase 2 Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejec … Ended
  2023-508736-62-00 4 2024-08-08 Heart failure (HF) with reduced ejection fraction (HFrEF)
• A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to … Ended
  2023-504564-42-00 4 2024-04-08 Moderate to Severe Rheumatoid Arthritis
• HIV: Budigalimab and/or ABBV-382 in People Living with HIV on Stable Antiretroviral Therapy Ended
  2023-505900-53-00 4 2024-04-08 HIV infection
• Effect of intravenous Lidocaine bolus on the median effective concentration (EC50) of Propofol during target controlled infusion (TCI : Schn … Ended
  2023-509888-24-00 6 2024-04-08 Gastroscopy
• TACTIVE-U: An Umbrella Study to Investigate the Safety and Antitumor Activity of vepdegestrant (ARV-471) in Combination With Other Medicines … Ended
  2023-507125-41-00 9 2024-03-25 Advanced or Metastatic Breast Cancer
• SAFE study: Stopping Antibiotics after 3 days for the treatment of FEbrile Neutropenia in Haematology patients, a randomized open-label non- … Ended
  2022-500389-84-00 6 2024-02-16 Febrile neutropenia
• "Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (MIRANDA)" Ended
  2023-505543-39-00 5 2024-02-12 Chronic Obstructive Pulmonary Disease (COPD)
• A study to test whether BI 456906 helps people living with overweight or obesity who do not have diabetes to lose weight Ended
  2022-502529-17-00 5 2024-01-18 Obesity
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the … Ended
  2023-503614-80-00 5 2023-12-14 Pulmonary Arterial Hypertension
• Extension Study to Assess Batoclimab in Participants with TED. Ended
  2024-512650-21-00 5 2023-12-13 Thyroid Eye Disease (TED)
• A randomized, double-blind, placebo-controlled, multicenter, adaptive phase III trial to investigate the efficacy and safety of vilobelimab … Ended
  2023-506250-20-00 5 2023-12-11 ulcerative pyoderma gangrenosum
• A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety, and tolerability of intravenous ganaxolone added to s … Ended
  2022-502540-12-00 5 2023-11-09 Refractory Status Epilepticus (RSE)
• A study to investigate response to ompenaclid combined with FOLFIRI plus bevacizumab in patients with advanced or metastatic colorectal canc … Ended
  2023-503356-27-00 4 2023-09-07 Metastatic colorectal cancer that is resistant to the currently approv

Showing 361–384 of 445 trials